WO2002054080A3 - Proteins, genes and their use for diagnosis and treatment of vascular response - Google Patents

Proteins, genes and their use for diagnosis and treatment of vascular response Download PDF

Info

Publication number
WO2002054080A3
WO2002054080A3 PCT/GB2001/005774 GB0105774W WO02054080A3 WO 2002054080 A3 WO2002054080 A3 WO 2002054080A3 GB 0105774 W GB0105774 W GB 0105774W WO 02054080 A3 WO02054080 A3 WO 02054080A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascular response
treatment
vrpis
diagnosis
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/005774
Other languages
French (fr)
Other versions
WO2002054080A2 (en
Inventor
Eugene H Herman
Gordon D Holt
Frank D Sistare
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
US Department of Health and Human Services
Original Assignee
Oxford Glycosciences UK Ltd
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd, US Department of Health and Human Services filed Critical Oxford Glycosciences UK Ltd
Priority to EP01272729A priority Critical patent/EP1368647A2/en
Priority to AU2002222308A priority patent/AU2002222308A1/en
Publication of WO2002054080A2 publication Critical patent/WO2002054080A2/en
Anticipated expiration legal-status Critical
Publication of WO2002054080A3 publication Critical patent/WO2002054080A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of vascular response, for monitoring the effectiveness of vascular response treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. In particular, the screening of drug candidates for their ability to induce a vascular response, Vascular Response-Associated Features (VRFs), detectable by two-dimensional electrophoresis of blood, serum or plasma are described. The invention further provides Vascular Response-Associated Protein Isoforms (VRPIs) detectable in blood, serum or plasma, preparations comprising isolated VRPIs, antibodies immunospecific for VRPIs, and kits comprising the aforesaid.
PCT/GB2001/005774 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of vascular response Ceased WO2002054080A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01272729A EP1368647A2 (en) 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of vascular response
AU2002222308A AU2002222308A1 (en) 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of vascular response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26038700P 2000-12-29 2000-12-29
US60/260,387 2000-12-29
US25497701P 2001-10-24 2001-10-24
US60/254,977 2001-10-24

Publications (2)

Publication Number Publication Date
WO2002054080A2 WO2002054080A2 (en) 2002-07-11
WO2002054080A3 true WO2002054080A3 (en) 2003-09-12

Family

ID=27791427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005774 Ceased WO2002054080A2 (en) 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of vascular response

Country Status (3)

Country Link
EP (1) EP1368647A2 (en)
AU (1) AU2002222308A1 (en)
WO (1) WO2002054080A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006122946A (en) * 2003-11-28 2008-01-10 Астразенека Аб (Se) ANTIBODIES
EP2445539A4 (en) * 2009-06-26 2015-05-20 Five Prime Therapeutics Inc Therapeutic antibody target validation and screening in vivo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (en) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of rheumatoid arthritis
WO2001069261A2 (en) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (en) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of rheumatoid arthritis
WO2001069261A2 (en) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLENNOW K ET AL: "CEREBROSPINAL FLUID 'NEURONAL THREAD PROTEIN' COMES FROM SERUM BY PASSAGE OVER THE BLOOD-BRAIN BARRIER", NEURODEGENERATION, ACADEMIC PRESS LTD., LONDON, GB, vol. 4, no. 2, 1995, pages 187 - 193, XP001011872, ISSN: 1055-8330 *
BLOOD COAGULATION & FIBRINOLYSIS: AN INTERNATIONAL JOURNAL IN HAEMOSTASIS AND THROMBOSIS. ENGLAND OCT 1990, vol. 1, no. 4-5, October 1990 (1990-10-01), pages 499 - 503, ISSN: 0957-5235 *
DATABASE MEDLINE [online] October 1990 (1990-10-01), SHAINOFF J R ET AL: "Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease.", XP002224790, Database accession no. NLM1983461 *
LI XIN PING ET AL: "A two-dimensional electrophoresis database of rat heart proteins.", ELECTROPHORESIS, vol. 20, no. 4-5, April 1999 (1999-04-01), pages 891 - 897, XP002224262, ISSN: 0173-0835 *
MANABE T ET AL: "A NONDENATURING PROTEIN MAP OF HUMAN PLASMA PROTEINS CORRELATED WITH A DENATURING POLYPEPTIDE MAP COMBINING TECHNIQUES OF MICRO TWO-DIMENSIONAL GEL ELECTROPHORESIS", ELECTROPHORESIS, WEINHEIM, DE, vol. 20, no. 4/5, April 1999 (1999-04-01), pages 830 - 835, XP001070186, ISSN: 0173-0835 *
MATTILA K M ET AL: "ALTERED BLOOD-BRAIN-BARRIER FUNCTION IN ALZHEIMER'S DISEASE?", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 89, no. 3, 1994, pages 192 - 198, XP001011873, ISSN: 0001-6314 *
MENEGATTI MARZIA ET AL: "Identification of four novel polymorphisms in the Aalpha and gamma fibrinogen genes and analysis of association with plasma levels of the protein.", THROMBOSIS RESEARCH, vol. 103, no. 4, 15 August 2001 (2001-08-15), pages 299 - 307, XP002224789, ISSN: 0049-3848 *
RIDKER PAUL M: "Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?", ANNALS OF INTERNAL MEDICINE, vol. 130, no. 11, 1 June 1999 (1999-06-01), pages 933 - 937, XP002224263, ISSN: 0003-4819 *

Also Published As

Publication number Publication date
AU2002222308A1 (en) 2002-07-16
WO2002054080A2 (en) 2002-07-11
EP1368647A2 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
HUP0003533A2 (en) Interleukin-18 binding proteins, their preparation and use
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
FR2751986B1 (en) GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION
ATE353974T1 (en) METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
NO20050497L (en) Use of CETP inhibitors and optionally HMG COA reducible inhibitors and / or antihypertensive agents
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
Demettre et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients
WO2001013117A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2000018912A3 (en) Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
WO1999047925A3 (en) Methods and compositions for diagnosis of rheumatoid arthritis
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2002054080A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular response
DE60101305D1 (en) DPI-6, A THERAPEUTIC BIOMARKER IN NEUROLOGICAL DISEASES
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
Hasson et al. Antibody zymography: a novel adaptation of zymography to determine the protease-neutralising potential of specific antibodies and snake antivenoms
WO2002054079A3 (en) Proteins, genes and their use for diagnosis and treatment of cardiac response
WO2002046768A3 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma
WO2001013118A3 (en) Methods and compositions for diagnosis of hepatoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001272729

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001272729

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001272729

Country of ref document: EP